Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $68.7752W HIGH $132.49
Volume
6.21 M
Value Traded
506.20 M
Short % Float
4.32%
Days to Cover
4.1
-0.81%Week
+8.82%1 Month
+9.25%3 Month
+6.99%6 Month
-53.94%5 Year
+158.16%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
34.02 B
EPS (TTM)
6.02
P/E Ratio
13.68
Ent. Value
41.53 B
Total Shares
413.18 M
Float Shares
405.38 M
Insiders
0.23%
Institutions
99.86%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|
PoA blends historical approval base rates, trial design score and FDA review track record.
ZTS Catalyst Timeline
Dated clinical, regulatory and corporate events for Zoetis Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Zoetis Inc.
259Total events
3Upcoming
143Tier-1 (high impact)
2019 to 2027Coverage
Upcoming catalysts 2
Event history 50
▲FDA ApprovalFDA Decision
FDA approved Convenia RTU for Dogs (cefovecin injectable suspension) for susceptible bacterial skin infections in dogs
susceptible bacterial skin infections in dogssource ↗
▲FDA ApprovalFDA Decision
FDA approval of Convenia RTU for Dogs
long-acting antibacterial injection for dogssource ↗
▲CHMP Positive OpinionPortelaApprovedEx-US Regulatory
CVMP recommended granting marketing authorization
pain associated with osteoarthritis in catssource ↗
▲Emergency Use AuthorizationFDA Decision
FDA grants Emergency Use Authorization for Simparica Trio for New World screwworm
New World screwworm (Cochliomyia hominivorax) larvae (myiasis) in dogs and puppiessource ↗
▲Product LaunchPortelaApprovedPost-Market
Commercial launch of Portela (relfovetmab) in Canada and the European Union
osteoarthritis pain in catssource ↗
▲EU ApprovalPortelaApprovedEx-US Regulatory
European Commission grants marketing authorization for Portela
pain associated with osteoarthritis in catssource ↗
▲Product LaunchLeniviaApprovedPost-Market
Launch of Lenivia in Canada and the European Union
osteoarthritis painsource ↗
▲EU ApprovalEx-US Regulatory
European Commission grants marketing authorization for Poulvac Procerta HVT-ND
Newcastle disease and Marek's disease in chickenssource ↗
▲Product LaunchLeniviaApprovedPost-Market
Lenivia (izenivetmab injection) launched in Canada and the European Union
osteoarthritis painsource ↗
▲PublicationPresentation
Peer-reviewed study of Simparica Trio vs NexGard Plus heartworm counts published
heartworm in dogssource ↗
▲Emergency Use AuthorizationFDA Decision
FDA Emergency Use Authorization for Simparica Trio for New World screwworm
New World screwworm infestations in dogs and puppiessource ↗
▲Ex-US ApprovalEx-US Regulatory
Japan and Mexico approval of Alfaxan Multidose 4% for cat sedation
sedation of catssource ↗
▲FDA ApprovalFDA Decision
U.S. and Mexico approval of Fostera PRRS Needle-free microdose
porcine reproductive and respiratory syndrome in pigssource ↗
▲Brazil Label ExpansionEx-US Regulatory
Additional claim in Brazil for Vanguard B Oral
Bordetella bronchiseptica protection in dogssource ↗
▲Canada Label ExpansionEx-US Regulatory
Additional claim in Canada for Vanguard crLyme
subclinical arthritis caused by Borrelia burgdorferi in dogssource ↗
▲Product LaunchPost-Market
Launch of Lenivia for dogs in Great Britain
long-acting osteoarthritis pain in dogssource ↗
▲FDA ApprovalFDA Decision
Swiss approval of Portela for cats
long-acting osteoarthritis pain in catssource ↗
▲Emergency Use AuthorizationDectomax-CA1ApprovedFDA Decision
FDA issues EUA for Dectomax/Dectomax-CA1 for NWS in additional species
New World screwworm (Cochliomyia hominivorax) larvae (myiasis) in dairy cattle, swine, sheep, and deersource ↗
▲Canada ApprovalEx-US Regulatory
Approval in Canada for Convenia RTU
bacterial skin infections and urinary tract infections in dogssource ↗
▲Thailand ApprovalEx-US Regulatory
Apoquel Chewable approved in Thailand
relief of allergic itch in dogssource ↗
▲Japan ApprovalKetofenApprovedEx-US Regulatory
Ketofen approved in Japan for cattle pain management
cattle pain managementsource ↗
▲Product LaunchPost-Market
Zoetis launches additional traits for CLARIFIDE Plus and updates DWP$ Index
dairy cattle geneticssource ↗
▲Partnership / LicenseCorporate
Zoetis enters definitive agreement to acquire Neogen's animal genomics business
◆Oral PresentationPresentation
Zoetis CFO to participate in investor conferences in March 2026
◆Oral PresentationPresentation
Zoetis participation in Bank of America Securities 2026 Animal Health Summit
◆Quarterly UpdateCorporate
Q4 and Full Year 2025 Financial Results Webcast and Conference Call
▲Product LaunchPortelaApprovedPost-Market
Portela commercially available in the European Union
pain associated with osteoarthritis in catssource ↗
▲PublicationPresentation
Peer-reviewed publication in Parasites & Vectors of head-to-head laboratory study of Simparica Trio vs NexGard Plus against ML-resistant heartworm isolate ZoeLA
heartworm disease (Dirofilaria immitis) prevention in dogssource ↗
▲Quarterly UpdateCorporate
Zoetis declares first quarter 2026 dividend of $0.53 per share, a 6% increase
▲Canada ApprovalLeniviaApprovedEx-US Regulatory
Lenivia approved in Canada for OA pain in dogs
osteoarthritis pain in dogssource ↗
▲CHMP Positive OpinionLeniviaApprovedEx-US Regulatory
Lenivia received positive CVMP opinion for EU marketing authorization
osteoarthritis pain in dogssource ↗
▲EU ApprovalPortelaApprovedEx-US Regulatory
Portela received marketing authorization in EU
osteoarthritis pain in catssource ↗
▲Brazil Label ExpansionCytopointApprovedEx-US Regulatory
Cytopoint labeled for allergic dermatitis in Brazil
allergic dermatitissource ↗
▲Ex-US Label ExpansionEx-US Regulatory
Simparica Trio new label indications in Australia, Canada, UK
parasiticidessource ↗
Past FDA Catalysts and PDUFA Decisions
How ZTS actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| No matching catalysts | ||||||
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
Zoetis Inc. is not a drug developer. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every ZTS program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| FULLER JULIEOfficer (Executive Vice President) | Option | 799 1,862 held | $0.00 | 09/30/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in ZTS
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Avidity Partners | 0.7 % (-58.8 %) | 13.87 M | 71.00 K | -70.42% ( -169.00 K) |
Ownership Trends
ZTS Short Interest
Shares sold short, counted twice a month.
4.32%
Short % of Float
of tradable shares sold short
17.5M
Shares Sold Short
-4.9% vs prior count
4.1 Moderate
Days to Cover
trading days of normal volume to buy every short share back
4.3M
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How ZTS ranks across every disease it competes in
Competitive Position is a premium feature
See how ZTS ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialZTS News
ZTS▲ +3.7%today
Zoetis to Participate in the Jefferies Global Healthcare Conference in London
Zoetis CFO Jay Saccaro will attend the Jefferies Global Healthcare Conference in London on November 16, 2026. The event features a fireside chat accessible via live webcast. A replay will be available on the Zoetis website after the presentation concludes.
Read more →ZTS▼ -7.9%on this news
Zoetis Announces Third Quarter 2026 Results; Highlights Progress Advancing Innovation Across Diversified Portfolio and Narrows Full Year 2026 Revenue Guidance, Raises Full Year 2026 Adjusted EPS Guidance
Zoetis reported third-quarter 2026 revenue of $2.4 billion, a 1% decrease from the previous year. The U.S. segment revenue fell by 6%, while the international segment grew by 4%. Adjusted diluted EPS increased by 3% to $1.75, and the company narrowed its full-year revenue guidance. New product approvals from the FDA were achieved ahead of schedule.
Read more →ZTSZoetis Receives FDA Approval for Convenia® RTU for Dogs (cefovecin injectable suspension), Helping More Medium and Large Dogs Access Single-Injection Treatment
Zoetis has received FDA approval for Convenia RTU for Dogs, an injectable treatment for bacterial skin infections. This single-injection solution provides up to 14 days of antibiotic coverage, improving compliance for dog owners. The formulation is more concentrated, making it practical for dogs of all sizes. It builds on the established Convenia portfolio, trusted by veterinarians for over a decade.
Read more →ZTSZoetis Appoints Iris Knobloch to its Board of Directors
Zoetis Inc. has appointed Iris Knobloch to its Board of Directors, effective December 1, 2026. Knobloch brings significant experience in consumer strategy and digital transformation, having served on various boards, including Deezer S.A. and Lazard, Inc. Her expertise is expected to support Zoetis in navigating industry dynamics and enhancing customer connections.
Read more →ZTSZoetis Declares Fourth Quarter 2026 Dividend
Zoetis Inc. has announced a dividend of $0.53 per share for Q4 2026. The payment will occur on December 1, 2026, for shareholders on record as of October 30, 2026. This move reflects the company's commitment to returning value to its shareholders.
Read more →ZTSNew Peer-Reviewed Publication on Laboratory Study That Demonstrated Simparica Trio® Protected 3x More Dogs From Infection With a Resistant Heartworm Isolate Than NexGard® Plus¹
A new study published in Parasites & Vectors shows that Zoetis' Simparica Trio protects more dogs from heartworm infection than NexGard Plus. Simparica Trio demonstrated 99.5% efficacy against the resistant heartworm isolate ZoeLA, while NexGard Plus showed 98.1%. The study found significantly fewer adult heartworms in dogs treated with Simparica Trio.
Read more →ZTSZoetis to Host Webcast and Conference Call on Third Quarter 2026 Financial Results
Zoetis Inc. will conduct a webcast and conference call on November 5, 2026, to discuss its third quarter financial results. CEO Kristin Peck and CFO Jay Saccaro will present the findings and answer questions from analysts. The event will be accessible to the public via the Zoetis website.
Read more →ZTSZoetis to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
Zoetis Inc. has announced its participation in the Morgan Stanley 24th Annual Global Healthcare Conference. CEO Kristin Peck and CFO Jay Saccaro will engage in a fireside chat on September 14, 2026. The event will be accessible via a live audio webcast, with a replay available afterward.
Read more →ZTSZoetis Receives Emergency Use Authorization for Simparica Trio® (sarolaner, moxidectin, and pyrantel chewable tablets) for Treatment of New World Screwworm Infestations in Dogs and Puppies
Zoetis Inc. has received Emergency Use Authorization from the FDA for Simparica Trio, a treatment for New World screwworm infestations in dogs and puppies. This authorization allows the use of the chewable tablets to combat infestations caused by the larvae of Cochliomyia hominivorax. The treatment aims to protect pets from the harmful effects of these larvae.
Read more →ZTSZoetis Announces Second Quarter 2026 Results
Zoetis reported second quarter 2026 results with flat revenue of $2.5 billion and net income of $691 million. The company revised its full year revenue guidance down to $9.120 - $9.320 billion, reflecting a decline in the U.S. companion animal market. Despite challenges, the international segment saw an 8% revenue increase, and Zoetis continues to advance its product pipeline.
Read more →ZTSZoetis Appoints Jay Saccaro as Chief Financial Officer and Chief Operating Officer
Zoetis Inc. appointed James (Jay) Saccaro as CFO and COO, effective August 17, 2026. Saccaro, previously at GE HealthCare, will oversee finance and global manufacturing. Wetteny Joseph will serve as a Special Advisor until early 2027 to ensure a smooth transition. The leadership change aims to enhance operational excellence and support future growth.
Read more →ZTSZoetis Launches Portela® (relfovetmab) in Canada and the European Union
Zoetis has launched Portela® (relfovetmab) in Canada and the EU, the first long-acting anti-NGF monoclonal antibody therapy for cats. This treatment provides up to three months of osteoarthritis pain relief with a single injection. Clinical trials showed it to be effective and well tolerated, addressing a significant gap in feline pain management.
Read more →ZTSZoetis Launches Lenivia® (izenivetmab injection) in Canada and the European Union
Zoetis Inc. has launched Lenivia® (izenivetmab injection) in Canada and the EU, a new long-acting monoclonal antibody therapy for osteoarthritis pain management. This innovative treatment can provide relief for up to three months with a single subcutaneous injection. The launch is supported by a decade of research and a successful nine-month European field study.
Read more →ZTSZoetis Announces Agreement to Acquire VitalRADS, Accelerating Diagnostic Capabilities
Zoetis Inc. has announced its agreement to acquire VitalRADS, a veterinary teleradiology services platform. This acquisition builds on a previous partnership and will enhance Zoetis' Global Diagnostics portfolio. The integration will provide around-the-clock access to board-certified veterinary specialists, improving reference laboratory services.
Read more →ZTSZoetis Receives European Commission Marketing Authorization for Poulvac® Procerta® HVT-ND
Zoetis has been granted marketing authorization by the European Commission for its Poulvac® Procerta® HVT-ND vaccine. This approval allows the company to market the vaccine in Europe, enhancing its portfolio in the poultry sector. The vaccine aims to provide protection against specific viral diseases in poultry.
Read more →ZTSZoetis to Host Webcast and Conference Call on Second Quarter 2026 Financial Results
Zoetis has announced a webcast and conference call to discuss its financial results for the second quarter of 2026. The event aims to provide insights into the company's performance and future outlook. Further details regarding the timing and access to the call will be provided by the company.
Read more →ZTSZoetis to Participate in Upcoming Investor Conferences
Zoetis is set to participate in several upcoming investor conferences. Details regarding the specific conferences and the content of their presentations have not been disclosed in the article. This participation indicates Zoetis's ongoing engagement with investors and stakeholders in the biopharma sector.
Read more →ZTSZoetis Declares Third Quarter 2026 Dividend
Zoetis has announced its third quarter dividend for 2026. The declaration is part of the company's ongoing commitment to return value to its shareholders. Further details about the dividend amount and payment date were not provided in the announcement.
Read more →ZTS▼ -21.5%on this news
Zoetis Announces First Quarter 2026 Results
Zoetis Inc. reported its Q1 2026 financial results, showing a 3% revenue increase to $2.3 billion, with net income at $601 million. The U.S. segment faced challenges, with an 8% revenue decline due to heightened competition and price sensitivity among pet owners. In contrast, the International segment saw a 17% revenue increase, driven by strong demand for companion animal products. The company remains optimistic about its pipeline of potential blockbusters and ongoing innovation efforts.
Read more →ZTSZoetis to Host Webcast and Conference Call on First Quarter 2026 Financial Results
Zoetis has announced a webcast and conference call to discuss its financial results for the first quarter of 2026. The event aims to provide insights into the company's performance during this period. Further details regarding the timing and access to the call will likely be shared closer to the date.
Read more →About Zoetis Inc.
Headquarters10 SYLVAN WAY, PARSIPPANY, NJ, 07054
BIOPHARMAWATCH ELITE
Trade the next ZTS catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $24/mo billed annually.
Cancel anytime